KTTA (Pasithea Therapeutics) Institutional Ownership: 38.66% (As of Jul. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KTTA Pasithea Therapeutics Corp KTTA
29 GF Score
Price $0.45
! 2 Warning Signs
View Full Analysis

What is Pasithea Therapeutics Institutional Ownership?

Pasithea Therapeutics KTTA -3.89% 29 Institutional Ownership is 38.66% as of Jul. 21, 2026. GuruFocus rates KTTA with a GF Score™ of 29/100. The stock has 2 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Pasithea Therapeutics's institutional ownership is 38.66%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Pasithea Therapeutics's Insider Ownership is 2.70%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Pasithea Therapeutics's Float Percentage Of Total Shares Outstanding is 98.90%.

Pasithea Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Pasithea Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pasithea Therapeutics Institutional Ownership Chart

Pasithea Therapeutics Historical Data

The historical data trend for Pasithea Therapeutics can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 3.87 4.25 4.19 1.68 1.83 1.82 1.96 3.75 2.88 3.36
KTTA
29GF Score
Pasithea Therapeutics Corp KTTA
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pasithea Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 38.66% mean?
Pasithea Therapeutics (KTTA) has a Institutional Ownership of 38.66% as of Jul. 21, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Pasithea Therapeutics and its competitors.
Is Pasithea Therapeutics' Institutional Ownership too high?
Pasithea Therapeutics' current Institutional Ownership is 38.66%. Overall, Pasithea Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Pasithea Therapeutics' Institutional Ownership compare to CELU and GRTX?
Pasithea Therapeutics' Institutional Ownership of 38.66% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Pasithea Therapeutics and its competitors. Pasithea Therapeutics's current Institutional Ownership is 38.66%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pasithea Therapeutics stock overvalued right now?
Pasithea Therapeutics (KTTA) has a current Institutional Ownership of 38.66%. The current Institutional Ownership is 38.66%. Pasithea Therapeutics' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Pasithea Therapeutics (KTTA), the current Institutional Ownership is 38.66% as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pasithea Therapeutics Business Description

Address 1111 Lincoln Road, Suite 500, Miami Beach, FL, USA, 33139
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.
29GF Score

Get the complete analysis for KTTA

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.45
Price